Aberdeen Group plc Grows Stock Position in Allogene Therapeutics, Inc. $ALLO

Key Points

• Aberdeen Group plc increased its stake in Allogene Therapeutics by 138.0%, owning approximately $1.27 million worth of shares as of the latest SEC filing.
• Allogene Therapeutics reported earnings of ($0.23) EPS, surpassing the consensus estimate of ($0.28), while analysts expect an annual EPS of ($1.28).
• Currently, Alogene Therapeutics has a consensus rating of "Moderate Buy" from analysts, with a target price set at $8.44.

Aberdeen Group plc increased its holdings in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 138.0% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 867,250 shares of the company's stock after acquiring an additional 502,868 shares during the period. Aberdeen Group plc owned approximately 0.40% of Allogene Therapeutics worth $1,266,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of ALLO. Lynx1 Capital Management LP grew its position in shares of Allogene Therapeutics by 75.3% during the 4th quarter. Lynx1 Capital Management LP now owns 10,874,723 shares of the company's stock valued at $23,163,000 after acquiring an additional 4,672,349 shares during the period. Foresite Capital Management VI LLC acquired a new stake in Allogene Therapeutics in the 4th quarter worth about $7,345,000. Patient Square Capital LP acquired a new stake in Allogene Therapeutics in the 4th quarter worth about $3,174,000. Dimensional Fund Advisors LP boosted its holdings in Allogene Therapeutics by 30.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,561,626 shares of the company's stock worth $7,586,000 after buying an additional 831,146 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in Allogene Therapeutics by 1,732.2% in the 4th quarter. BNP Paribas Financial Markets now owns 849,658 shares of the company's stock worth $1,810,000 after buying an additional 803,284 shares during the last quarter. 83.63% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ALLO. Oppenheimer lowered their price objective on Allogene Therapeutics from $10.00 to $9.00 and set an "outperform" rating on the stock in a report on Wednesday, May 14th. Royal Bank Of Canada reiterated an "outperform" rating and issued a $10.00 price objective on shares of Allogene Therapeutics in a report on Wednesday, May 14th. Citizens Jmp cut Allogene Therapeutics from an "outperform" rating to a "market perform" rating in a report on Wednesday, May 14th. Truist Financial lowered their price objective on Allogene Therapeutics from $14.00 to $10.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Finally, JMP Securities reiterated a "market perform" rating on shares of Allogene Therapeutics in a report on Monday, August 4th. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $8.44.

Allogene Therapeutics Stock Down 1.3%

Shares of Allogene Therapeutics stock traded down $0.02 on Tuesday, hitting $1.15. 1,281,404 shares of the company were exchanged, compared to its average volume of 4,389,411. The stock has a market capitalization of $254.05 million, a price-to-earnings ratio of -1.03 and a beta of 0.35. The company has a 50-day moving average price of $1.21 and a 200 day moving average price of $1.43. Allogene Therapeutics, Inc. has a 1-year low of $0.86 and a 1-year high of $3.78.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last issued its earnings results on Wednesday, August 13th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.05. Research analysts forecast that Allogene Therapeutics, Inc. will post -1.28 EPS for the current year.

Allogene Therapeutics Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).